Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 01/06/2024 am IST			5-day change	1st Jan Change
1.714 ^USD	-0.06%		-12.10%	-45.06%

31/05	European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	MT
24/05	European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	MT

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

May 16, 2024

Akari Therapeutics, Plc announced a private placement that it has issued unsecured convertible, short-term promissory notes to individual investors such as Samir R. Patel and Ray Prudo for the gross proceeds of $500,000 in May 2024.

Latest news about Akari Therapeutics, Plc

European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	24/05	MT
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
Akari Therapeutics, Plc announced that it has received $0.5 million in funding	16/05	CI
Akari Therapeutics, Plc Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
Akari Therapeutics, plc Announces the Resignation of Rachelle Jacques from the Board of Directors	08/05	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	02/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
Akari Therapeutics, Plc Announces CEO Changes	01/05	CI
Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc	01/05	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	29/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	24/04	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	23/04	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	15/04	MT
ADRs End Lower, Leju Holdings Ltd. Declines 72%	13/04	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	12/04	MT
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	12/04	DJ

Chart Akari Therapeutics, Plc

Duration

Period

More charts

Company Profile

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AKARI THERAPEUTICS, PLC	-45.06%	13.58M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs